Biological E acquires Akorn India


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ biological-e-acquires-akorn-india-ramps-up-covid-vaccine-manufacturing
Hyderabad based BE acquires Akorn India to ramp up Covid vaccine manufacturing facilities

Hyderabad-based prescribed drugs and biologics firm Biological E. (BE) has introduced the acquisition of Akorn India, a subsidiary of U.S. agency Akorn Inc.

The acquisition, for an undisclosed sum, comes days after , whose COVID-19 vaccine candidate (Advert26.COV2.S) is present process medical trials.

Describing it as a strategic acquisition, BE stated it’s within the means of growing a COVID-19 vaccine and could possibly use the services at Akorn India’s plant in Paonta Sahib, Himachal Pradesh for business scale manufacture of the vaccine on the applicable time.

“The timing of this acquisition is fortuitous as it will immediately allow us to expand our capacity to manufacture our investigational COVID-19 vaccine,” Biological E Managing Director Mahima Datla stated.

Akorn plant has a fully staffed sterile injectable manufacturing facility with a 39,000 sq m of built-up area spread over a 14-acre campus. It has a capacity for about 135 million units with the potential for immediate expansion of a further 30 million units.

Mahima Datla, Managing Director, Biological E. said, “We are happy to have made a strategic investment in acquiring Akorn India. We would leverage BE’s and Akorn India’s capabilities to enhance our supply capacities both in vaccines and in generic injectables. The timing of this acquisition is fortuitous as it will immediately allow us to expand our capacity to manufacture our investigational COVID-19 vaccine. With these capacities, we would be in a position to offer over 1 billion doses per annum.”

Commenting on the acquisition, Narender Dev Mantena, Director, BioE Holdings, who heads BE’s novel vaccines initiative, said “We are glad to have acquired Akorn India, which is known for its injectables and speciality sterile pharmaceuticals capabilities. This acquisition will allow us to expand our capacities to meet the increasing demands of our speciality generic injectables for the US and EU customers. This acquisition will pave a new way for BE and add significant value for our business operations and global supply of our products.”

Tags : #BiologicalE #Hyderabad #AkornIndia #CovidVaccine #LatestPharmaMergersAug17 #LatestPharmaUpdatesAug17 #LatestPharmaNewsAug17

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026